New drug combo aims to shrink tumors in advanced colorectal cancer
NCT ID NCT07585279
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new form of chemotherapy (liposomal irinotecan) combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18 to 75 will be randomly assigned to one of three treatment groups. The goal is to see if the new combination shrinks tumors and improves survival, while also checking safety and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIPOSOMAL IRINOTECAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness together ease the burden of advanced cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Blood test may reveal hidden cancer spread without scans
- Mouth bacteria may predict colon cancer drug resistance
- New cocktail attack on stubborn colon cancer
- New chemo cocktail aims to slow advanced colon cancer